Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis

Journal of Internal Medicine

Volumn 245, Issue 1, 1999, Pages 47-55

  Geiss, H C ^a   Parhofer, K G ^a   Schwandt, P ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Atorvastatin; Hypercholesterolaemia; LDL apheresis; Simvastatin

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

APHERESIS; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SCREENING; HUMAN; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; CORONARY DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS; MALE; PYRROLES; SIMVASTATIN; TREATMENT OUTCOME;

EID: 0032965710     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.00401.x     Document Type: Article

References (23)

1. 1 Lea AP, McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidemias. Drugs 1997; 53: 828-47.
2. 2 Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group. Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79: 1248-52.
3. 3 Bakker-Arkema RG. Davidson MH. Goldstein RJ. Davignon J. Isaacsohn JL. Weiss SR et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275: 128-33.
4. 4 Nawrocki JW. Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ et al. Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678-82.
5. 5 Bakker-Arkema RG, Shurzinske L, Davidson M, McKenney J, Stein E, Schrott H, Black DM. Two-year comparison of safety and efficacy of atorvastatin and lovastatin. Atherosclerosis 1997; 134: 119 [abstract of the 11th International Symposium on Atherosclerosis, Paris].
6. 6 Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 1527-31.
7. 7 Dart A. Jerums G, Nicholson G, d'Emden M, Hamilton-Craig I. Tallis G et al. A multiccnter, double-blind, one year study comparing safety and efficacy of atorvastatin vs. simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997; 80: 39-44.
8. 8 Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R. Fayyad R, Black D. Comparison of one-year efficacy and safely of atorvastatin vs. lovastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79: 1475-81.
9. 9 Bertolini S, Bittolo Bon G, Campbell LM, Farnier M, Langan J. Mahla C et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997; 130: 191-7.
10. 10 Black DM. Comparison of the efficacy and safety of atorvastatin with simvastatin in patients with primary hypercholesterolemia. Atherosclerosis 1997; 134: 120 [abstract of the 11th International Symposium on Atherosclerosis, Paris].
11. 11 Dujovne CA. New lipid lowering drugs and new effects of old drugs. Curr Opin Lipid 1997; 8: 362-8.
12. 12 Naoumova RP, Dunn S, Rallidis L, Abu-Muhana O, Neuwirth C, Rendell NB et al. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J Lipid Res 1997; 38: 1496-500.
13. 13 Burnett JR. Wilcox LJ. Telford DE, Kleinstiver SJ, Barrett HR, Newton RS, Huff MW. Inhibition of HMR-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Arterioscler Thromb Vasc Biol 1997; 17: 2589-600.
14. 14 Marais D, Naoumova RP, Firth JC, Penny C, Neuwirth CKY, Thompson GR. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res 1997; 38: 2071-8.
15. 15 The Expert Panel. National Cholesterol Education Program: Second report of the Expert Panel on Detection, Evaluation and Treatment of high blood cholesterol in adults (adult treatment panel II). Circulation 1994; 89: 1329-445.
16. 16 Task Force of the European Society of Cardiology, European Atherosclerosis Society, and European Society of Hypertension. Prevention of coronary heart disease in clinical practice: recommendations. Atherosclerosis 1994; 110: 121-61.
17. 17 Kroon AA, van Asten WNJC, Stalenhoef AFH. Effect of apheresis on low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Int Med 1996; 125: 945-54.
18. 18 Friedewald WTR, Levy RI, Fredrickson DS. Estimation of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
19. 19 The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153-62.
20. 20 Schettler V, Schuff-Werner Schettler E, Wieland K, Müller GA. Effect of atorvastatin vs. simvastatin in patients undergoing regular LDL-apheresis (ASLA I). Atherosclerosis 1997; 134: 133 [abstract of the 11th International Symposium on Atherosclerosis, Paris].
21. 21 Richter WO, Jacob BG, Ritter MM, Sühler K, Vierneisl K, Schwandt P. Three-year treatment of familial hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism 1993; 42: 888-94.
22. 22 Bakker-Arkema RG, Black DM, Nawrocki JW. An overview of the clinical safely profile of atorvastatin: a new, more effective HMG-CoA reductase inhibitor. Atherosclerosis 1997; 134: 119 [abstract of the 11th International Symposium on Atherosclerosis, Paris].
23. 23 Bakker-Arkema RG, Best J, Fayyad R, Heinonen TM, Marais AD, Nawrocki JW, Black DM. A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. Atherosclerosis 1997; 131: 17-23.